GSK Wins US Approval for Hepatitis B Drug Hibsago
GSK said Hibsago was cleared under priority review and breakthrough therapy designation. Phase III B—Well data supported the decision, according to the company.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.